156 related articles for article (PubMed ID: 32514592)
1. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.
Jeannet R; Daix T; Formento R; Feuillard J; François B
Intensive Care Med; 2020 Sep; 46(9):1769-1771. PubMed ID: 32514592
[No Abstract] [Full Text] [Related]
2. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.
Urra JM; Cabrera CM; Porras L; Ródenas I
Clin Immunol; 2020 Aug; 217():108486. PubMed ID: 32479985
[TBL] [Abstract][Full Text] [Related]
3. Simplified immune-dysregulation index: a novel marker predicts 28-day mortality of intensive care patients with COVID-19.
Chen H; Wang J; Su N; Bao X; Li Y; Jin J
Intensive Care Med; 2020 Aug; 46(8):1645-1647. PubMed ID: 32435824
[No Abstract] [Full Text] [Related]
4. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
Liu J; Li S; Liu J; Liang B; Wang X; Wang H; Li W; Tong Q; Yi J; Zhao L; Xiong L; Guo C; Tian J; Luo J; Yao J; Pang R; Shen H; Peng C; Liu T; Zhang Q; Wu J; Xu L; Lu S; Wang B; Weng Z; Han C; Zhu H; Zhou R; Zhou H; Chen X; Ye P; Zhu B; Wang L; Zhou W; He S; He Y; Jie S; Wei P; Zhang J; Lu Y; Wang W; Zhang L; Li L; Zhou F; Wang J; Dittmer U; Lu M; Hu Y; Yang D; Zheng X
EBioMedicine; 2020 May; 55():102763. PubMed ID: 32361250
[TBL] [Abstract][Full Text] [Related]
5. Viral and host factors related to the clinical outcome of COVID-19.
Zhang X; Tan Y; Ling Y; Lu G; Liu F; Yi Z; Jia X; Wu M; Shi B; Xu S; Chen J; Wang W; Chen B; Jiang L; Yu S; Lu J; Wang J; Xu M; Yuan Z; Zhang Q; Zhang X; Zhao G; Wang S; Chen S; Lu H
Nature; 2020 Jul; 583(7816):437-440. PubMed ID: 32434211
[TBL] [Abstract][Full Text] [Related]
6. Telomere length, epidemiology and pathogenesis of severe COVID-19.
Tsilingiris D; Tentolouris A; Eleftheriadou I; Tentolouris N
Eur J Clin Invest; 2020 Oct; 50(10):e13376. PubMed ID: 32880939
[No Abstract] [Full Text] [Related]
7. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
8. Lymphopenia during the COVID-19 infection: What it shows and what can be learned.
Tavakolpour S; Rakhshandehroo T; Wei EX; Rashidian M
Immunol Lett; 2020 Sep; 225():31-32. PubMed ID: 32569607
[No Abstract] [Full Text] [Related]
9. Lymphopenia and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Hospitalized Obstetric Patients.
Duffy CR; Hart JM; Modest AM; Hacker MR; Golen T; Li Y; Zera C; Shainker SA; Mehrotra P; Zash R; Wylie BJ
Obstet Gynecol; 2020 Aug; 136(2):229-231. PubMed ID: 32433451
[TBL] [Abstract][Full Text] [Related]
10. COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
[No Abstract] [Full Text] [Related]
11. One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4
Wang M; Luo L; Bu H; Xia H
Int J Infect Dis; 2020 Jul; 96():148-150. PubMed ID: 32335339
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection.
Altmann DM; Boyton RJ
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680954
[TBL] [Abstract][Full Text] [Related]
13. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis.
Zhao Q; Meng M; Kumar R; Wu Y; Huang J; Deng Y; Weng Z; Yang L
Int J Infect Dis; 2020 Jul; 96():131-135. PubMed ID: 32376308
[TBL] [Abstract][Full Text] [Related]
14. A Case of COVID-19 and
Menon AA; Berg DD; Brea EJ; Deutsch AJ; Kidia KK; Thurber EG; Polsky SB; Yeh T; Duskin JA; Holliday AM; Gay EB; Fredenburgh LE
Am J Respir Crit Care Med; 2020 Jul; 202(1):136-138. PubMed ID: 32412848
[No Abstract] [Full Text] [Related]
15. Immunological features of coronavirus disease 2019 in patients with cancer.
Thibaudin M; Fumet JD; Bon M; Hampe L; Limagne E; Ghiringhelli F
Eur J Cancer; 2020 Nov; 139():70-80. PubMed ID: 32977223
[TBL] [Abstract][Full Text] [Related]
16. The allergist/immunologist, the Janus gatekeeper of inflammation, COVID-19 and beyond.
Bellanti JA; Settipane RA
Allergy Asthma Proc; 2020 Nov; 41(6):395-396. PubMed ID: 33109305
[No Abstract] [Full Text] [Related]
17. Coronavirus disease 2019 as a particular sepsis: a 2-week follow-up of standard immunological parameters in critically ill patients.
Monneret G; Cour M; Viel S; Venet F; Argaud L
Intensive Care Med; 2020 Sep; 46(9):1764-1765. PubMed ID: 32488343
[No Abstract] [Full Text] [Related]
18. Prostaglandin D
Gupta A; Chander Chiang K
Med Hypotheses; 2020 Oct; 143():110122. PubMed ID: 32759007
[TBL] [Abstract][Full Text] [Related]
19. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19).
Foldes D; Hinton R; Arami S; Bain BJ
Am J Hematol; 2020 Jul; 95(7):861-862. PubMed ID: 32298486
[No Abstract] [Full Text] [Related]
20. Lymphopenia in COVID-19: Therapeutic opportunities.
Fathi N; Rezaei N
Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
